Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

Share Price Information for IQ-AI (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.40
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.20 (14.286%)
Open: 1.50
High: 1.50
Low: 1.50
Prev. Close: 1.50
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMAGING BIOMETRICS ANNOUNCES PARTNERSHIP

11 Apr 2018 07:00

RNS Number : 4904K
Flying Brands Limited
11 April 2018
 

 

 

FLYING BRANDS' SUBSIDIARY IMAGING BIOMETRICS ANNOUNCES DISTRIBUTION PARTNERSHIP WITH AI EXCHANGE PLATFORM, ENVOY AI

 

IB Neuro and IB Delta T1 Maps are now available on EnvoyAI's artificial intelligence Exchange

 

 

Flying Brand's newly acquired subsidiary Imaging Biometrics®, LLC ("IB"), a medical imaging software company specialising in advanced visualisation and analytics, has entered into a distribution agreement with EnvoyAI, a leading artificial intelligence ("AI") Exchange platform. IB Neuro, the premier magnetic resonance ("MR") imaging dynamic susceptibility contrast (DSC) perfusion solution, and IB's Delta T1 mapping algorithm, are now available for purchase on the EnvoyAI Exchange.

 

Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI said, "We recently added Imaging Biometrics' FDA cleared post-processing solutions to the EnvoyAI Exchange. The proprietary quantitative and automated algorithms contained in IB Neuro and IB Delta Suite provide clinicians with incredible value by producing unique imaging biomarkers that enable them to accurately monitor treatment response in brain tumor patients."

 

"This partnership with EnvoyAI enables immediate and widespread access to our proven and quantitative imaging biomarkers for neuro radiologists, neuro-oncologist, and neuro surgeons," said Michael Schmainda, CEO of IB. "The need to accurately quantify changes in brain tumor patients is becoming more important and yet increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents. The exclusive technology contained in IB's products overcome these difficulties and, through the unique additional information made available, aid the treatment team's ability to rapidly and objectively assess whether patients are responding to treatment. We are delighted to participate on the EnvoyAI Exchange and look forward to providing sophisticated imaging solutions to benefit clinicians and their patients."

 

About EnvoyAI (www.envoyai.com)

EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialisation processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Imaging Biometrics® LLCImaging Biometrics develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

About Flying Brands PLC

Flying Brands PLC (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGMDVGGGRZM
Date   Source Headline
16th Jul 201511:15 amRNSHolding(s) in Company
13th Jul 20152:57 pmRNSConversion of Convertible Loan Notes
29th May 20154:21 pmRNSResult of AGM
1st May 201511:28 amRNSNotice of AGM and Transfer of CLN to Director-Rep
30th Apr 20156:28 pmRNSNotice of AGM and Transfer of CLN to Director
17th Apr 201511:00 amRNSPreliminary Results
11th Mar 20152:16 pmRNSResult of EGM
13th Feb 20157:00 amRNSBoard Changes and Notice of EGM
31st Dec 20147:00 amRNSUpdate
7th Nov 20143:24 pmRNSSale of Retreat Farm
27th Aug 20147:00 amRNSInterim Results Announcement
11th Jun 201411:42 amRNSResult of AGM
29th Apr 20143:33 pmRNSAnnual Report and Results Announcement
8th Apr 20147:00 amRNSDirectorate Change
9th Jan 201411:30 amRNSDirectorate Change
15th Nov 20137:00 amRNSInterim Management Statement
28th Aug 20137:00 amRNSHalf Yearly Report
13th Jun 20137:00 amRNSResult of AGM
26th Apr 20137:00 amRNSAnnual Report and Results Announcement
25th Apr 20134:59 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
23rd Jan 20131:31 pmRNSRefinancing of Flowers Direct and Board changes
19th Nov 20127:00 amRNSTrading Update
31st Aug 20127:00 amRNSHalf Yearly Report
1st Aug 20127:00 amRNSClosure of Growing and Live Dispatch Business
9th Jul 20127:00 amRNSDisposal
13th Jun 201210:25 amRNSResult of AGM
6th Jun 20128:05 amRNSTransfer to Standard Listing
28th May 20123:03 pmRNSMerger Update
22nd May 201211:15 amRNSInterim Management Statement
16th May 20122:00 pmRNSMerger Update
4th May 201210:27 amRNSResult of EGM
1st May 20127:00 amRNSCompletion of Sale
30th Apr 20126:36 pmRNSFinal Results- Replacement
30th Apr 20127:00 amRNSAnnual Results Announcement
27th Apr 201211:47 amRNSResult of EGM
11th Apr 20124:24 pmRNSPosting of Circular and Notices of two EGMs
5th Apr 201211:34 amRNSRe. Flowers Direct
30th Mar 20127:54 amRNSPurchase of Assets
30th Mar 20127:00 amRNSProposed disposals
20th Mar 20123:00 pmRNSMerger Update
21st Feb 20127:59 amRNSProposed sale of the Gifts Division
24th Jan 20127:00 amRNSTrading Statement
20th Dec 201112:07 pmRNSApproaches for Certain of the Company's Assets
7th Dec 20117:00 amRNSCompletion of disposals
30th Nov 201110:58 amRNSResult of EGM
15th Nov 20117:00 amRNSPosting of Circular to Shareholders
3rd Nov 20117:00 amRNSInterim Management Statement & Directorate Change
26th Sep 20117:00 amRNSProposed sale of certain non-core property assets
23rd Sep 20117:00 amRNSTrading Statement
29th Jul 20117:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.